Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

HMB-001

Bispecific antibody · developed by Hemab ApS

Phase 1/2 Most advanced trial

COAG Developer

1 Registered trials

What is HMB-001?

HMB-001 is a bispecific antibody. It is being studied as a prophylactic treatment to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Pathways: hemostasis
Therapy area: Hematology
Developer: Hemab ApS (COAG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06211634	Phase 1/2	Glanzmann Thrombasthenia	Active not recruiting	COAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glanzmann Thrombasthenia

More from Hemab ApS

HMB-002 Phase 1/2 HMB-003 Phase 1 Sutacimig Phase 2

Sources

ClinicalTrials.gov NCT06211634

Updated Oct 11, 2026. Something wrong or missing? Report it on the COAG page.

Follow COAG, the company behind HMB-001

See COAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COAG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z